Mar 03, 2017 8:30am EST NEMUS Bioscience and Catalent to Advance NB1222 into Human Dosage Formulation Development
Jun 16, 2016 8:00am EDT Nemus Bioscience Announces Enhanced Ocular Tissue Concentration by the Proprietary Prodrug of Tetrahydrocannabinol (NB1111) - Associated With a Superior Decline in Intra-Ocular Pressure (IOP) in an Animal Model
Jun 10, 2016 8:58am EDT Nemus Bioscience, Inc. Announces Letter of Intent to License Biosynthetic Technology to Manufacture Its Proprietary Cannabinoid Molecules From Teewinot Life Sciences Corp.
Jun 02, 2016 8:30am EDT NEMUS Bioscience Identifies Unique Cannabidiol (CBD) Derivative as a Lead Candidate in Its Neuropathy-Related Pain Management Program
Feb 08, 2016 8:00am EST NEMUS Bioscience, Inc. Signs Agreement With Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredients
Dec 22, 2015 8:30am EST Nemus Enters Into Research Agreement With the University of Mississippi to Develop Cannabinoid-Based Therapies for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Dec 16, 2015 8:30am EST NEMUS Announces In-Licensing of Cannabidiol (CBD) Derivatives From the University of Mississippi
